PCSA

Processa Pharmaceuticals (PCSA)

Processa Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:PCSA

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/12	03 : 19	Edgar (US Regulatory)	Form DEFR14A - Revised definitive proxy soliciting materials	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/06/11	21 : 20	GlobeNewswire Inc.	Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/05/29	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/05/29	05 : 49	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/05/22	05 : 13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/05/22	05 : 10	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/05/11	05 : 16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/05/06	21 : 00	GlobeNewswire Inc.	Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/04/30	21 : 00	GlobeNewswire Inc.	Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/04/11	21 : 00	GlobeNewswire Inc.	Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/03/28	21 : 15	GlobeNewswire Inc.	Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/03/25	21 : 15	GlobeNewswire Inc.	Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/02/22	07 : 25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/02/21	22 : 15	GlobeNewswire Inc.	Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/02/15	03 : 00	GlobeNewswire Inc.	Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/02/06	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/02/06	22 : 30	GlobeNewswire Inc.	Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/02/02	08 : 32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/02/02	06 : 22	GlobeNewswire Inc.	Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/02/01	06 : 37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/01/31	00 : 46	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/01/30	06 : 15	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/01/29	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/01/26	23 : 04	GlobeNewswire Inc.	Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/01/25	22 : 35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/01/25	22 : 30	GlobeNewswire Inc.	Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/01/19	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/01/19	21 : 45	GlobeNewswire Inc.	Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/01/18	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PCSA	Processa Pharmaceuticals Inc
2024/01/18	21 : 45	GlobeNewswire Inc.	Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split	NASDAQ:PCSA	Processa Pharmaceuticals Inc